Teniposide

From Anvita Health Wiki

Contents 1 Introduction 2 Indications 3 Dosage 4 Adverse-effects 5 Drug-interactions 6 Laboratory 7 Mechanism-of-action 8 More General Terms 9 Additional Terms 10 Internet Database 11 References

Introduction

• Tradename: Vumon.

Indications

• treatment of refractory childhood, acute lymphocytic leukemia ( ALL) in combination with other antineoplastic agents
• non-Hodgkin's lymphoma

Dosage

• Injection:

• formulated in polyethoxlated castor oil & dehydrated alcohol (43%): 10 mg/mL (5 mL)

• Solution:

• solutions containing 0.5-2 mg/mL remain stable for 4 hours & those containing 0.1-0.2 mg/mL remain stable for 6 hours

Adverse-effects

• common (> 10%)

• myelosuppression, leukopenia, neutropenia, thrombocytopenia, mucositis, nausea/vomiting, diarrhea, infection

• less common (1-10%)

• alopecia, rash, hypotension, hypersensitivity, fever, hemorrhage

• uncommon (< 1%)

• hepatic dysfunction, peripheral neurotoxicity, renal dysfunction, metabolic abnormalities

Drug-interactions

• plasma clearance of methotrexate may be slightly increased
• salicylate, sulfamethoxazole & tolbutamide displace teniposide from protein binding sites to a small, but significant extent

Laboratory

• test interactions: increases serum K+

Mechanism-of-action

• mitotic inhibitor
• topoisomerase inhibitor [2]

More General Terms

• epipodophyllotoxin
• antineoplastic agent (chemotherapeutic agent)

Additional Terms

• acute lymphoblastic leukemia (ALL)

Internet Database

PubChem: 34698
PubChem: 5396
PubChem: 5311475
PubChem: 5284623
PubChem: 452548
PubChem: 275784

References

1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
2. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 529
3. Department of Veterans Affairs, VA National Formulary

teniposide (Vumon)